Cellphire, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
2
Ending by 2030
Apr 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 18, 2027The maintenance fee for Thrombosomes as an Antiplatelet Agent Reversal Agent (US 11,701,388) comes due Jan 18, 2027. Unpaid by Jul 19, 2027, it lapses early.
- 2 fees due Mar 12 to 26, 2027 · next Mar 12
- 1 fee due May 14, 2027The maintenance fee for Materials and Methods for Producing Blood Products (US 11,813,572) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Treatment of von Willebrand disease (US 11,903,971) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for Platelets loaded with anti-cancer agents (US 11,965,178) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,486,617 | Methods for preparing freeze-dried platelets, compositions comprising freeze-dried platelets, and methods of use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,097,403 | Freeze-dried platelets, method of making and method of use as a diagnostic agent In force · From the USPTO record | In force | From the USPTO record | |
| US 12,378,523 | Platelets as delivery agents In force · From the USPTO record | In force | From the USPTO record | |
| US 11,752,468 | Materials and Methods for Producing Blood Products In force · High confidence | In force | High confidence | |
| US 11,813,572 | Materials and Methods for Producing Blood Products In force · High confidence | In force | High confidence | |
| US 12,208,122 | Methods of treating bleeding in a subject treated with an antiplatelet agent In force · From the USPTO record | In force | From the USPTO record | |
| US 11,701,388 | Thrombosomes as an Antiplatelet Agent Reversal Agent In force · Medium confidence | In force | Medium confidence | |
| US 11,903,971 | Treatment of von Willebrand disease In force · From the USPTO record | In force | From the USPTO record | |
| US 12,290,532 | Treatment of von Willebrand disease In force · From the USPTO record | In force | From the USPTO record | |
| US 11,529,587 | Materials and Methods for Producing Blood Products In force · High confidence | In force | High confidence |
Also on record, not counted in the 16: 1 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
7 pending · 2 abandoned · 31 no status recorded